– CANADA, Vancouver – LexaGene Holdings, Inc. (TSX: LXG | OTC: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced the appointment of Steve Mastrocola to its Board of Directors.
The company also announced that Daryl Rebeck has resigned from the Board and his position as the President of the Company, effective February 15, 2021.
“We are extremely excited to have Steve join our board. He brings strong leadership skills, a wealth of knowledge, and connections in the industry that will be critical for LexaGene to meet its growth goals in 2021 and beyond.” said CEO and Founder, Dr. Jack Regan.
Dr. Regan added, “I’m immensely grateful to Daryl for being my partner and helping me found this company four years ago. I would like to thank him for all his hard work and leadership and wish him great success in his future endeavors.”
About Steve Mastrocola
As a board member, Mr. Mastrocola brings almost 40 years of accounting and auditing experience working with public and private companies. Mr. Mastrocola recently retired from Ernst & Young LLP (EY) after 19 years, where he was a senior assurance partner and led EY’s New England Assurance Practice for several years. Prior to EY, Mr. Mastrocola was an assurance partner at Arthur Andersen LLP. Through his 40-year career at leading auditing firms, he served primarily emerging and growth-oriented companies in the life science sector with products in medical devices and diagnostics. Mr. Mastrocola is a Certified Public Accountant with extensive experience in various financial transactions including IPOs, debt financings, mergers and acquisitions, revenue recognition, internal controls and corporate governance, including compliance matters. Mr. Mastrocola is also a member of LaunchPad Venture Group and serves on the Boards of Partners for Youth with Disabilities and the New England Aquarium.
About LexaGene Holdings Inc.
LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press ‘go’. The MiQLab™ system delivers excellent sensitivity, specificity, and breadth of detection and can return results in approximately one hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.
For more information : https://lexagene.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.